tbuckley/cabot-search huggingface dataset:
A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Authors: Shaji K. Kumar, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Mehdi Hamadani, A. Keith Stewart, Vivek Roy, Parameswaran Hari, Robert Vescio, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Neeraj Gupta, Ai-Min Hui, Paul G. Richardson
Journal: Blood (2012)
Initial clinical experience with intraaortic balloon pumping in cardiogenic shock
Authors: A. Kantrowitz
Journal: JAMA (1968)

Our intraaortic cardiac assistance system for patients in cardiogenic shock following myocardial infarction consists of a catheter and balloon inserted through a femoral arteriotomy into the thoracic aorta. The pumping chamber, activated by helium, is synchronized with the heart by signals from the electrocardiogram or the central aortic pressure transducer. Pumping improved two patients' circulatory status; one survived. Two patients died before pumping could begin; in another, an abdominal aortic aneurysm prevented insertion of the pump. Thrombosis did not occur during pumping; hemolysis appeared minimal. Although final evaluation must await more data, balloon pumping appears to be effective in cardiogenic shock. Further study may establish a place for the procedure in myocardial infarction without cardiogenic shock and in low cardiac output syndromes associated with open-heart surgery.
Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients.
Authors: Neal Shore, Judd Boczko, Naveen Kella, Brian Joseph Moran, Fernando J. Bianco, E. David Crawford, Jonathan Nelson, Rajesh R. Kaldate, Kirstin M. Roundy, Michael K. Brawer, Mark L. Gonzalgo
Journal: Journal of Clinical Oncology (2015)

e16042 Background: The cell cycle progression (CCP) test is a validated molecular assay that assesses risk of prostate cancer−specific disease progression and mortality when combined with standard clinicopathologic parameters. PROCEDE−1000 is the largest prospective registry to evaluate CCP test impact on personalizing prostate cancer treatment. Results of the final analysis of 1206 are presented. Methods: Untreated patients with newly diagnosed ( ≤ 6 months), clinically localized prostate adenocarcinoma were enrolled. The physician’s initial therapy recommendation (pre−CCP) was recorded on the first questionnaire. The CCP test was then conducted on prostate biopsy tissue. Three post−CCP questionnaires recorded the physician’s revised treatment recommendation, physician/patient treatment decision, and actual treatment administered. Changes in treatments between the pre-CCP and post−CCP questionnaires demonstrated the impact of CCP testing on treatment decisions at each stage. Results: There was a significant reduction in the treatment burden recorded at each successive evaluation (P < 0.0001), with mean number of treatments per patient decreasing from 1.72 pre-CCP test to 1.16 in actual follow-up. From pre-CCP therapy recommendation, the CCP risk score caused a change in actual treatment administered in 48% of patients; of these changes, 72% were reductions in treatment. These reductions occurred in radical prostatectomy (34%), radiation therapy (39% primary; 55% adjuvant), brachytherapy (46% interstitial; 63% HDR) and hormonal therapy (30% neoadjuvant; 50% concurrent) treatments. Although a considerably high percentage of patients (34.6%; 417/1206) were recommended for conservative management pre-CCP testing, a further 2.6% increase overall was recorded for non-interventional treatments during actual follow-up. Conclusions: The CCP risk assessment score has a significant impact in helping physicians and patients reach consensus on an appropriate personalized treatment decision, often with major reductions in interventional treatment burden.
COVER STORY
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Giant cavernous hemangioma of the esophagus
Authors: J. H. Feist
Journal: JAMA (1976)

VASCULAR lesions of the esophagus are extremely uncommon.<sup>1</sup>Reports of benign tumors in that location collected from 1912 to 1948 show that hemangiomas occurred in only 2.2% of the cases.<sup>2</sup>We report the following case because of its unusually interesting clinical features. <h3>Report of a Case</h3> A coal miner, aged 48, was referred with the diagnosis of tumor of the esophagus, demonstrated by esophagraphy. He had sought medical advice because of mild but progressive shortness of breath over a oneyear period, occasional belching, and epigastric discomfort. He had no other symptoms referrable to the chest or digestive system, and results of a physical examination were normal. Posteroanterior and lateral chest roentgenograms showed widening of the superior mediastinum, and a midmediastinal mass displacing the trachea anteriorly. Esophagoscopy (with a conventional open instrument) showed an extrinsic pressure defect without ulceration or mucosal lesions, and a mucosal biopsy report indicated chronic
Central Pain Mechanisms
Authors: Rudolph H. de Jong
Journal: JAMA (1978)

Melzack who, with Wall,<sup>1</sup>introduced the "gate control" concept of pain some dozen years ago now has added important new insights toward a better understanding of chronic pain mechanisms. Together with Loeser,<sup>2</sup>he develops a hypothesis that explains puzzling observations about phantom body pain below the level of transection in paraplegic persons. Clearly, when all neural traffic between a body area and the brain is interrupted mechanically, impulse conduction along classic spinal pain tracts is halted. Yet, from 5% to 10% of paraplegics suffer severe discomfort from phantom body pain. Even more baffling, phantom body pain is experienced following cordectomy—the complete removal of one or more spinal cord segments. These are observations for which the segmental dorsal horn gate-control system theory provides less than satisfactory answers.<sup>3</sup> The severity of pain in paraplegic patients often leads to several attempts at deafferentation of the phantom body site with methods
Blue Infusion
Authors: Lala Tanmoy Das
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Inflammatory Bowel Disease
Authors: P. Marteau
Journal: Endoscopy (2002)

This article reviews a selection of 50 papers on inflammatory bowel disease published between April 2000 and June 2001. The new information summarized here includes: the discovery of the association of the NOD2 gene with Crohn's disease; the role of bacteria and the modulating effects of probiotics; the inverse association of appendectomy and ulcerative colitis; progress in imaging based on magnetic resonance imaging and leukocyte scintigraphy; assessment of the value of anti-Saccharomyces cerevisiae antibodies in the screening of inflammatory bowel disease and differentiation between ulcerative colitis and Crohn's disease; and risk factors and management of dysplasia and cancer. This article does not review all therapeutic aspects, but focuses on smoking cessation; anti-tumor necrosis factor antibody treatments; the usefulness of measuring erythrocyte 6-thioguanine metabolite levels to optimize purine analogue therapy; strictureplasty; and the long-term results of ileoanal anastomosis.
Identification of Genes Associated with Tumor Suppression in Syrian Hamster Embryo Cells
Authors: Roger W. Wiseman, Jeffry C. Montgomery, Junichi Hosoi, Esther W. Hou, Charles J. Cochran, Patricia W. Lamb, J. Carl Barrett
Journal: Environmental Health Perspectives (1991)

Loss of a tumor-suppressor gene function appears to play a critical role in the multistep process of neoplastic transformation of Syrian hamster embryo (SHE) cells in vitro. Clonal variants of two independent, preneoplastic cell lines have been isolated that have either retained (termed supB+) or lost (termed supB-) the ability to suppress the tumorigenicity of a highly malignant benzo[alpha]pyrene-transformed SHE cell line (BP6T) in cell hybrids. We have pursued several approaches in an attempt to identify genes that are responsible for tumor suppression in these cells. The only consistent differences detected in two-dimensional gel analyses of supB+ and supB- cellular proteins were decreases in the levels of two high molecular weight isoforms of tropomyosin in supB- cells. Differential screening of a supB+ cDNA library for genes that are preferentially expressed in supB+ cells yielded cDNA clones for four genes, i.e., collagen type II, collagen type IX, H19, and a previously unidentified gene (clone 5). Nuclear run-on assays suggested that higher transcription rates were responsible for the increased steady-state levels of some of these transcripts in supB+ cells. DNA sequence comparisons showed that two copies of a 9 bp element, previously identified in each of the mouse H19 enhancers, were also present in the 5' flanking region of the rat type II collagen gene. A transcription factor that controls expression of the collagen and H19 genes through binding to this conserved motif would be an attractive candidate for the supB+ gene or at least a mediator of the supB+ phenotype.
<i>Manuel Pratique de Médecine Mentale</i>par la Dr. E. Régts, Ancien chef de chinique des maladies mentales à la Faculté de Médicine do Paris, &amp; c. Avec une Préface par M. Benjamin Ball. Ouvrage couronné par la Faculté de Médicine de Paris. Deuxième Edition, entièrement revue et corrigée. (A Practical Manual of Mental Medicine, by Dr. B. RÉgis, &amp; c., 2d edition, thoroughly revised and corrected.)
Authors: H. M. B.
Journal: American Journal of Psychiatry (1892)
Medical News
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lowering Cholesterol and the Incidence of Coronary Heart Disease-Reply
Journal: JAMA (1985)

<h3>In Reply.—</h3> Dr Adams is correct to point out that a statistical association of lower plasma cholesterol levels and reduced incidence of CHD need not imply that these findings are cause and effect. However, his speculations concerning the mechanism of this association are based, at least in part, on a misreading of the LRC-CPPT results. The statistic on which he bases his third conclusion that "cholestyramine dosage is not related to CHD frequency" was derived from a proportional-hazards model containing terms for both change in LDL cholesterol and packet count. The nonsignificance (<i>P</i>&gt;.85) of the packet-count term in this model implied the absence of a non-LDL—mediated effect of cholestyramine dosage on CHD incidence. When the term for change in LDL cholesterol levels was omitted from the model,<sup>1</sup>the term for packet count was significant (<i>P</i>=.037, for a one-sided alternative). These two models taken together demonstrate an
Depression
Authors: Janet M. Torpy
Journal: JAMA (2010)

Depression Aperson who feels sad all the time, has unexplained crying spells, or loses interest in usual activities may have major depression, a serious medical illness that should be distinguished from normal temporary feelings of sadness after a loss, such as the death of a relative or friend.The May 19, 2010, issue of JAMA is a theme issue on mental health that includes several articles about depression.This Patient Page is based on one previously published in the November 12, 2008, issue of JAMA.
BELGIUM
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
François Rabelais
Authors: Richard Warren
Journal: New England Journal of Medicine (1955)

IT is the distinction between a snicker and a laugh that has given Rabelais to the ages. For his was the big honest laugh, the "rire immense" understandable by and irresistible to all men. What is known of the life of this most human of humanists who entered medicine relatively late in life so that he might learn more about man?He was born at Chinon between 1483 and 1495, and died in 1553, probably at Lyons. It is natural that the details of the life of a man fond himself of the tall story should be so surrounded by . . .
Errata
Journal: BMJ (1898)

NEURON.-We do not know that the waters of Plombieres are imported.The chief part of the treatment at Plombieres consists in baths and other external application of the water.It is therefore unlikely that drinking the Plomnbieres water in England can have the same effect as a course of treatment at the spa itself.J.P.-The young woman should either decline the patient altogether, giving no reasons, or accept unconditionally, but intimating that she will not be a party to any concealment of what may take place in her house.In the event of abortion taking place the doctor should treat the case Just as he would any other case of abortion: but take care to do nothing that he would object to see published in the next issue of the local paper.J. M.-We know of no analysis of the medicine in question, but the drugs mentioned are of little importance.Rumex crispus is the "yellow dock," a common roadside plant.It contains tannin, chrysophanic acid and mucilage.It is said to be antiscorbutic.Geofrya mermis is the cabbage bark tree."It was many years ago official in the Dubtin Pharmacopcea, and was given in large doses as a cathartic and anthel- mintic.Malva sylvestris is the common mallow.It contains mucilage, and is a simple demuleent without any active properties.
Separating wheat from chaff of nutrition information
Authors: A. A. Skolnick
Journal: JAMA (1997)

TO HELP health reporters separate the wheat from the chaff of nutrition information, the American Heart Association (AHA) served a hearty helping of nutrition science at its 24th Health and Science Journalists Forum in Seattle, Wash. And to give them a taste of the difficulties of translating the latest research findings into dietary guidelines, one authority explained why Americans need to reduce their high salt consumption while another explained why they don't. <h3>Saline Solution?</h3> "Based on all the available experimental, epidemiologic, and clinical evidence, it seems prudent to include avoidance of a high salt intake as one component of a population-based, comprehensive nutritional strategy for the prevention of cardiovascular disease," said Theodore A. Kotchen, MD, professor and chair of the Department of Medicine at the Medical College of Wisconsin in Milwaukee. "New clinical trials call into question the benefits of salt restriction, in comparison with other dietary interventions—calorie restriction
Eleventh European Symposium on Hormones and Cell Regulation
Journal: JNCI Journal of the National Cancer Institute (1986)

Eleventh European Symposium on Hormones and Cell Regulation Get access JNCI: Journal of the National Cancer Institute, Volume 76, Issue 5, May 1986, Pages 981–982, https://doi.org/10.1093/jnci/76.5.981-f Published: 01 May 1986
Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST.
Authors: Gregory V. Goldmacher, Anuradha D. Khilnani, Robert H. I. Andtbacka, Jason J. Luke, F. Stephen Hodi, Aurelien Marabelle, Kevin Joseph Harrington, Andrea Marie Perrone, Archie N. Tse, David C. Madoff, Lawrence Howard Schwartz
Journal: Journal of Clinical Oncology (2020)

3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs have created a need for standardized evaluation of response to this unique treatment strategy. The Response Evaluation Criteria in Solid Tumors (RECIST) is not suitable for assessing responses separately for injected and noninjected tumors. Building on RECIST concepts, we propose an IT immunotherapy RECIST (itRECIST) to capture data and assess local and systemic responses in a standardized fashion for clinical trials involving IT immunotherapies. Methods: itRECIST will address the unique needs of IT immunotherapy trials but, where possible, aligns with RECIST 1.1 and iRECIST. It does not dictate which lesions to inject but provides guidelines for collecting data and assessing response as treatment evolves. Results: itRECIST enables overall response assessment, separate response assessments in injected and noninjected lesions, and continued assessment following modifications of therapy at initial progression. At baseline, lesions are classified into 4 categories: target injected, target noninjected, nontarget injected, and nontarget noninjected. After baseline, lesions can be reclassified from noninjected to injected if the investigator decides to change the lesions to inject, but target and nontarget designations never change. Overall response at each assessment is based on target lesion response (injected and noninjected), nontarget lesion response, and absence/appearance of new lesions. Noninjected lesion response is determined by comparing tumor burden with baseline and nadir values. Injected lesion assessment is based on visit-to-visit changes in the lesions injected during treatment and on a combined assessment once the patient is off treatment. A new response category is defined to capture progression that would be “confirmed” per iRECIST even though injected lesions are responding and therapy continues. Multiple examples have been created to aid in training and adoption. Conclusions: itRECIST is an important step toward a standardized method of response assessment for this promising and evolving therapeutic modality. The proposed guidelines can be adopted into trial protocols and routine clinical practice without the need for complex additional assessments by treating physicians. Until there is evidence to support wider use, itRECIST is intended only to support standardized collection of data and to facilitate exploratory analysis. Authors G.V.G. and A.D.K. contributed equally to this work.
Birth weight as a risk factor for raised blood pressure.
Journal: BMJ (1991)

Birth weight as a risk factor for raised blood pressure SIR, -Dr Daniel S Seidman and colleagues report that overweight in adolescence rather than low birth weight is the greater risk factor for raised blood pressure.'Previously, Barker et al had advocated nutritional supplementation for pregnant women to increase birth weight because they believed that this would reduce the risk of cardiovascular disease later in life.2'Dr Seidman and colleagues, echoing previous correspon- dence,4 suggest that this advice should be reconsidered.Barker et al were one of many groups